Am­gen makes pipeline cuts, but obe­si­ty plans re­main the fo­cus

While Am­gen didn’t re­veal much about up­com­ing read­outs for its high­ly-an­tic­i­pat­ed weight loss drugs dur­ing third-quar­ter earn­ings, the com­pa­ny did de­tail cer­tain changes to oth­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER